Papilla Type | 1 (n = 118) | 2 (n = 25) | 3 (n = 63) | 4 (n = 80) | p value |
---|---|---|---|---|---|
Age | 63 (50.5–74) | 65 (58–78) | 68 (55–77) | 67 (57.25–75) | 0.213 |
Gender-Male | 66 (55.93%) | 11 (44.00%) | 31 (49.21%) | 42 (52.50%) | 0.670 |
Indication | 0.589 | ||||
Stone | 87 (73.73%) | 16 (64.00%) | 49 (77.78%) | 57 (71.25%) | |
Cancer | 21 (17.80%) | 4 (16.00%) | 7 (11.11%) | 15 (18.75%) | |
Other | 10 (8.47%) | 5 (20.00%) | 7 (11.11%) | 8 (10.00%) | |
Diabetes | 27 (22.88%) | 6 (24.00%) | 21 (33.33%) | 22 (27.50%) | 0.490 |
Hypertension | 43 (36.44%) | 11 (44.00%) | 26 (41.27%) | 50 (62.50%) | 0.003** |
CVA | 8 (6.78%) | 2 (8.00%) | 3 (4.76%) | 6 (7.50%) | 0.912 |
CRI | 13 (11.02%) | 2 (8.00%) | 6 (9.52%) | 7 (8.75%) | 0.941 |
COPD | 3 (2.54%) | 0 (0.00%) | 5 (7.94%) | 1 (1.25%) | 0.084 |
CAD | 8 (6.78%) | 2 (8.00%) | 3 (4.76%) | 5 (6.25%) | 0.936 |
Cirrhosis | 6 (5.08%) | 2 (8.00%) | 3 (4.76%) | 3 (3.75%) | 0.860 |
Pre-cut | 8 (6.78%) | 5 (20.00%) | 10 (15.87%) | 8 (10.00%) | 0.117 |
Fail cannulation | 2 (1.69%) | 3 (12.00%) | 7 (11.11%) | 5 (6.25%) | 0.037* |
Pancreatic wire passage > 2 | 19 (16.10%) | 8 (32.00%) | 15 (23.81%) | 22 (27.50%) | 0.152 |
Pancreatic wire passage time | 0 (0–1) | 0 (0–1) | 1 (0–2) | 1 (0–3) | 0.036* |
Cannulation time | 0.001** | ||||
0–5 min | 67 (56.78%) | 8 (32.00%) | 19 (30.16%) | 29 (36.25%) | |
5–10 min | 31 (26.27%) | 4 (16.00%) | 21 (33.33%) | 23 (28.75%) | |
> =10 min | 20 (16.95%) | 13 (52.00%) | 23 (36.51%) | 28 (35.00%) | |
PAD Type | 0.128 | ||||
0 | 65 (55.08%) | 13 (52.00%) | 42 (66.67%) | 46 (57.50%) | |
2 | 12 (10.17%) | 7 (28.00%) | 5 (7.94%) | 10 (12.50%) | |
3 | 41 (34.75%) | 5 (20.00%) | 16 (25.40%) | 24 (30.00%) | |
Biopsy | 14 (11.86%) | 2 (8.00%) | 8 (12.70%) | 9 (11.25%) | 0.938 |
Sphincterotomy | 99 (83.90%) | 22 (88.00%) | 56 (88.89%) | 72 (90.00%) | 0.600 |
ERBD | 39 (33.05%) | 9 (36.00%) | 15 (23.81%) | 23 (28.75%) | 0.540 |
ERPD | 6 (5.08%) | 2 (8.00%) | 5 (7.94%) | 5 (6.25%) | 0.872 |
Stone extraction | 75 (63.56%) | 14 (56.00%) | 41 (65.08%) | 49 (61.25%) | 0.864 |
Lithotripsy | 2 (1.69%) | 1 (4.00%) | 2 (3.17%) | 2 (2.50%) | 0.880 |
EPBD | 2 (1.69%) | 3 (12.00%) | 0 (0.00%) | 1 (1.25%) | 0.003** |
Platelet | 230 (169.75–297.75) | 201 (155.5–310) | 197 (146–276) | 211 (152.5–281.75) | 0.426 |
PT | 10 (10–11) | 10 (9.8–10.7) | 10 (10–11.1) | 10 (10–10.9) | 0.502 |
APTT | 28 (26.2–29.93) | 27 (25.63–29.85) | 28 (26.4–30.35) | 28 (26.5–29.55) | 0.961 |
AST | 116 (47–227) | 53 (22.5–150.25) | 105 (46.75–205) | 104 (42.5–238) | 0.205 |
ALT | 140 (48–312.5) | 50 (21.5–125.5) | 125 (55–265) | 114 (44.5–309.75) | 0.022* |
Bilirubin | 3 (1.38–6.13) | 4 (0.45–5.1) | 4 (1.5–6.1) | 3 (1–5.08) | 0.503 |
Creatinine | 1 (0.67–0.97) | 1 (0.56–1.27) | 1 (0.66–1.06) | 1 (0.68–1.02) | 0.970 |
Complications | |||||
Perforation | 1 (0.85%) | 1 (4.00%) | 0 (0.00%) | 0 (0.00%) | 0.174 |
Pancreatitis | 8 (6.78%) | 5 (20.00%) | 1 (1.59%) | 5 (6.25%) | 0.020* |
Bleeding | 6 (5.08%) | 2 (8.00%) | 1 (1.59%) | 3 (3.75%) | 0.525 |
Cholangitis | 3 (2.54%) | 0 (0.00%) | 0 (0.00%) | 2 (2.50%) | 0.520 |